Login to Your Account



Fibrillex Misses; Neurochem Stock Drops By 28 Percent

By Karen Pihl-Carey


Tuesday, April 19, 2005
While Fibrillex demonstrated a positive trend in AA amyloidosis patients, a Phase II/III trial missed its primary endpoint, causing Neurochem Inc.'s stock plunge of 28.5 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription